A long systemic half-life is key for therapeutic proteins. To that end we have generated serum albumin-binding designed ankyrin repeat domains. These domains bind serum albumin of different species with nanomolar affinities, and have significantly improved pharmacokinetic properties both in mouse and cynomolgus monkey compared to non-serum albumin-binding DARPin ® domains. In addition, they exhibit high thermal stability and long storage stability, which is an essential feature for their use in drug development. Covalently linking a serum albumin-binding DARPin ® domain to domains with other target specificities results in improvements of multiple orders of magnitude in exposure and terminal half-life, both in mouse and cynomolgus monkey. Pharmacokinetic assessment of such constructs revealed terminal half-life values ranging from 27 h to 80 h in mouse, and from 2.6 days to 20 days in cynomolgus monkey. Extrapolation by allometric scaling on these findings suggests terminal half-life values of 5-50 days in human, indicating that pharmacokinetic properties in the range of monoclonal antibodies can be achieved with DARPin ® drug candidates. Such serum albumin-binding DARPin ® domains are thus valuable tools for the generation of multi-functional drugs with an extended in vivo half-life.
Introduction
Small high-potency binding proteins are ideal building blocks for next-generation protein therapeutics with properties beyond conventional IgG antibodies (Binz et al., 2005) . Such proteins are particularly interesting due to their high potency, good tissue targeting (Zahnd et al., 2010) , the straight-forward generation of multifunctional molecules enabling novel therapeutic approaches, and the ease of manufacture using microbial hosts. In order to take full advantage of their potential, their pharmacokinetic properties needs to be tailored to the therapeutic needs. Naturally, such small proteins possess a short plasma half-life due to efficient kidney filtration (Zahnd et al., 2010; Moeller and Tenten, 2013) . Various pharmacokinetic engineering methods have previously been established, including PEGylation (Harris and Chess, 2003) , polypeptide extension (Schellenberger et al., 2009) , HESylation (Liebner et al., 2014) , Fc fusions (Strohl, 2015) or albumin fusion (Sleep, 2015) amongst others (for review see Kontermann (2016) ). While these methods enable pharmacokinetic modulation, they typically come with a caveat affecting the advantageous properties of the protein drug, e.g. affecting straight-forward manufacturing or affecting pharmacological activity. An alternative approach for pharmacokinetic engineering of therapeutic proteins is to use fusions to serum albumin-binding proteins or peptides. Serum albumin is a 66 kDa plasma protein serving colloidal pressure control and transporting various lipophilic substances and having a long half-life of about 19 days in human (Peters, 1985) . Reaching a terminal half-life in that order of magnitude by binding to serum albumin would enable the generation of drug candidates with attractive pharmacokinetic properties. Several such approaches are known from literature and comprise the use of natural albumin-binding proteins such as the streptococcal protein G-derived albumin-binding domain (Linhult et al., 2002; Jonsson et al., 2008) , albumin-binding peptides (Dennis et al., 2002; Revets and Boutton, 2011) or antibody fragments binding to serum albumin (Holt et al., 2008; Müller et al., 2012; Van Roy et al., 2015) , which were generated by library selection technologies.
Designed ankyrin repeat proteins are small proteins that can be selected to bind target proteins with high affinity and specificity (Binz et al., 2004; Stumpp et al., 2008) . DARPin ® domains exhibit favorable biophysical properties including high thermal and thermodynamic stability (Binz et al., 2003; Plückthun, 2015) , which translate to a high storage stability, and their amenability for the generation of multi-functional protein therapeutics. 
Results and discussion
Selection of well-behaved serum albumin-binding DARPin ® domains
Ribosome display (Hanes et al., 1998; Binz et al., 2004; Zahnd et al., 2007) was used to select specific albumin-binding DARPin ® domains. After five selection rounds, pools of DNA were analyzed for individual serum albumin binders by crude extract ELISA screening. A number of serum albumin-specific binders were identified. In the following, individual serum albumin-specific DARPin ® domains are described in detail, with a particular focus on N2C DARPin ® domains, i.e. domains comprising one N-terminal capping repeat, two repeat modules, and one C-terminal capping repeat (see Binz et al., (2003) for details on nomenclature). In particular, we focus on N2C domains belonging to the sequence family of the serum albumin-binding DARPin ® domains currently being used in MP0250 in human and other DARPin ® drugs in preclinical development. Sequences of individual domains and proteins consisting of multiple domains are given in the Supplementary Information to this publication and are schematically represented in Fig. 1 . Individual such selected domains were expressed at levels between 0.2 g/l shakeflask culture in E. coli XL1 Blue as described previously (Binz et al., 2003) and more than 0.5 g/l shakeflask culture in E. coli BL21 with rich medium. The MRGSH6-tagged domains could readily be purified to near homogeneity using a single IMAC step. In a first analysis step, selected DARPin ® domains were subjected to biophysical and storage stability analyses. The results of these analyses are shown in Supplementary Table 1 and Fig. 2 . In fluorescence-based thermal stability measurements, the domains exhibited mid-points of thermal denaturation (maxima of the derivative of the measured curve) ranging between Tm = 78°C and Tm = 81.5°C at pH 7.4 (Supplementary Table 1) , and between Tm = 74.5°C and Tm = 79.5°C at pH 5.8 (Supplementary Table 1) . These values are expected from previous thermal unfolding experiments for N2C molecules and confirm the high thermal stability of designed ankyrin repeat proteins. A high thermal stability in turn can be a good predictor for long storage stability. Storage stability was assessed by incubating the proteins for 1 month at 40°C in PBS, followed by a comparative assessment by size-exclusion 
Nanomolar affinity and broad species cross-reactivity
Human serum albumin is present in the blood at a concentration of about 600 μM (Peters, 1985) . In circulation, the equilibrium between free serum albumin binder and binder complexed with serum albumin is expected to be almost completely at the side of the complex across a very broad range of affinities of the binder. Typical serum albumin binders do show serum albumin dissociation constants in the high nM to mid pM range (Dennis et al., 2002; Linhult et al., 2002; Holt et al., 2008; Revets and Boutton, 2011; Müller et al., 2012; Van Roy et al., 2015) , and they all exhibit attractive pharmacokinetic properties. The serum albumin-binding DARPin ® domains presented here exhibit affinities ranging from 11nM to 21nM for human serum albumin at pH 7.4 (Table I ). Our goal was to generate DARPin ® domains that can bind serum albumin of different species. The selected domains showed binding to serum albumin of human, cynomolgus monkey, mouse, rat, and dog, with mid-nanomolar affinities (Table I ). This broad species selectivity enables the use of the same serum albumin-binding DARPin ® domains from research through to the application in man. Importantly, low nanomolar-affinity binding of serum albumin of the different species was confirmed for the domains at pH 6 (Table I) . This is desired, as serum albumin-binding is particularly important during the FcRnmediated endosomal recycling of serum albumin, where the pH is known to be lower. The serum albumin-binding DARPin ® domains even bind slightly stronger to the serum albumin variants of different species at lower pH. The slightly higher affinity measured at pH 6 compared to pH 7.4 could hint at histidines being involved in the binding site either at the side of serum albumin or e.g. His48 in the designed ankyrin repeat domain. Interestingly, the latter is located just next to a Gly47Ser framework-mutation concerning the highly conserved glycine of the beta-turn of the ankyrin repeat. Further experiments would be needed to elucidate the role of these two residues. ELISA experiments indicate that DARPin ® domain #1 is able to bind a protein consisting of domains 1 and 2 of HSA (data not shown), whereas the FcRn binding site is located on domain 3 of HSA. This indicates that its binding to serum albumin is unlikely to interfere with FcRn-mediated serum albumin recycling.
Serum albumin-binding DARPin ® domains lead to improved pharmacokinetic properties
In mouse pharmacokinetic experiments the non-serum albuminbinding DARPin ® domain #5 is eliminated within minutes with no measurable blood levels beyond 4 h. No terminal half-life was determined with the setup measured due to the very fast systemic clearance of the protein (Table II and Fig. 3 ). This is in line with a previously reported measurement of a non-serum albumin-binding DARPin ® domain which exhibited a loss of 90% of the initial radioactivity after 7.5 min (Zahnd et al., 2010) . We chose to analyze the serum albumin-binding DARPin ® domains #1 and #3, whose amino acid sequence differs by two amino acids, to evaluate the impact on the pharmacokinetic profile. Indeed, DARPin ® domains binding to serum albumin exhibit clearly improved pharmacokinetic properties ( Fig. 3) , with domain #1 exhibiting a terminal half-life of 2.3 days (55 h; Table II and Fig. 3 ), and domain #3 exhibiting a terminal is limited by the half-life of cynomolgus monkey serum albumin, which was reported to be about 7-9 days (Deo et al., 1974 (Holt et al., 2008) . Another serum albumin-binding antibody fragment had a terminal half-life in mouse of 12 h (Hoefman et al., 2015) . These terminal half-life values appear to be slightly lower than the ones measured for the serum albumin-binding DARPin ® domains. In rhesus monkeys, terminal half-lives of albumin-binding antibody fragments were claimed to be in a range of 8.0 days to 12.5 days (Beirnaert et al., 2007) , which is comparable to the half-life measured for DARPin ® domains in cynomolgus monkey. A serum albumin-binding peptide exhibited a terminal half-life of 2.3 h in rabbits compared to a terminal half-life in the minute's range for a non-albumin-binding peptide (Dennis et al., 2002) .
Extending the half-life of protein therapeutics using serum albumin-binding DARPin ® domains
As a further step we assessed the ability of the serum albumin-binding DARPin ® domains in improving the pharmacokinetic properties of DARPin ® domains with other functionalities. To that end, a set of fusion proteins was generated ( Fig. 1 ; sequences see Supplementary Information). We chose to work with Pro-Thr-rich polypeptide linkers, as we believe the more rigid nature of Pro-Thr-rich polypeptide linkers leads to a good functionality of the individual domains (George and Heringa, 2002; Ruiz et al., 2016) compared to the classical Gly-Ser-rich polypeptide linkers, which are more flexible and appear to be ideal to link normally associated domains in a single genetic construct, such as e.g. the immunoglobulin domains as used in scFvs (Chen et al., 2013) . The proteins were expressed and purified as described for the single-domain proteins. The proteins were tested in mouse and cynomolgus monkey pharmacokinetic experiments (Fig. 3 , Table II ). In mouse pharmacokinetic experiments, different fusion proteins exhibited terminal half-lives in the range of 0.9 days to 1.8 days (Fig. 3 , Table II ). Similarly, these fusion proteins exhibited terminal half-lives in the range of 2.7 days to 10.6 days (Fig. 3 , Table II ) in cynomolgus monkeys, corresponding to an increase by a factor ranging from 338 to 1325 compared to a non-serum albuminbinding DARPin ® domain. Importantly, the maximum values observed are in the range of the terminal half-lives of the serum albumin of the respective species. Constructs with a long terminal half-life in mouse also exhibit a long terminal half-life in cynomolgus monkey. Similarly, constructs with a short terminal half-life in mouse also exhibit a short terminal half-life in cynomolgus monkey. This finding indicates a good scalability of the pharmacokinetic parameters across species and supports the possibility for extrapolation to the situation in human. A construct with a Pro-Thr-rich polypeptide linker exhibited slightly improved terminal half-life compared to a construct comprising a Gly-Ser-rich polypeptide linker (Table II) . A detailed analysis of DARPin ® drug candidate MP0250 indicates that the target-binding activities of individual DARPin ® domains are not affected upon transition to a multi-domain construct (Binz et al., 2017) . A number of similar approaches of fusing albumin-binding polypeptides to other protein domains are known, including fusion approaches with peptides (Dennis et al., 2002; Nguyen et al., 2006; Revets and Boutton, 2011) , albumin-binding domains (Stork et al., 2007; Tolmachev et al., 2007; Hopp et al., 2010; Frejd, 2012; Orlova et al., 2013) and antibody fragments (Holt et al., 2008; Walker et al., 2010; Müller et al., 2012; O'Connor-Semmes et al., 2014; Goodall et al., 2015; Hoefman et al., 2015; Van Roy et al., 2015) . Serum albumin-binding peptide fusion were used to improve the terminal half-life of antibody fragments from 24 min (bare antibody fragment) to 10.4 h (fusion) (Dennis et al., 2002) in mouse, or from 1.28 h to 19.7 h in mouse (Nguyen et al., 2006) , or from 31.2 h to 37.6 h in cynomolgus monkey (Revets and Boutton, 2011) . The albumin-binding domain of streptococcal protein G (ABD) was used to improve the pharmacokinetic profiles of the Fab fragment of Herceptin (2.1 h to 20.9 h improvement in terminal half-life in mouse) (Schlapschy et al., 2007) , a diabody (5.6 h up to 47.5 h in mouse) (Stork et al., 2007; Hopp et al., 2010) , or small helical proteins (38 min to 35.8 h, or 30 min to 41 h, in mouse) (Tolmachev et al., 2007; Orlova et al., 2013) , amongst others (Frejd, 2012) . Similar effects were achieved using serum albuminbinding shark antibody fragments (Müller et al., 2012) , other serum albumin-binding antibody fragments (Holt et al., 2008; Walker et al., 2010; O'Connor-Semmes et al., 2014; Goodall et al., 2015; Hoefman et al., 2015; Van Roy et al., 2015) . Overall, the serum albumin-binding DARPin ® domains can be used to create multidomain DARPin ® domains with pharmacokinetic properties that resemble the ones of serum albumin. The approach of using serum albumin-binding polypeptides as genetic fusion partner has various advantages over other serum halflife extension techniques. Direct fusion to serum albumin yields similar pharmacokinetic properties, yet does not allow for bacterial production. PEGylation, HESylation and polypeptide extension approaches typically are less efficient in improving pharmacokinetic properties and PEGylation and HESylation require chemical modification complicating the production process. The half-lives reported here indicate that the albumin-binding approach yields similar pharmacokinetic properties as seen for monoclonal antibodies. In addition this technology allows to take advantage of the high stability of DARPin ® domains and the possibility of producing therapeutic proteins efficiently in bacteria.
Maximizing terminal half-life -surprising avidity effect
There are contradicting data on the effect of serum albumin affinity/ avidity and half-life extension. Studies with peptides (Dennis et al., 2002; Nguyen et al., 2006; Revets and Boutton, 2011 ) suggest a correlation between serum albumin affinity and half-life extension. The peptides used in these studies were of mid nM affinities. Interestingly, a study comparing a construct comprising one albumin-binding domain (Kd = 11.2 nM) with a construct comprising two albumin-binding domains (apparent Kd = 2.5 nM) revealed no change in pharmacokinetic properties of the construct in mouse, indicating that nM affinity is sufficient for albumin-binding proteins, and no benefit is gained when using higher affinity or valency (Hopp et al., 2010) . Despite these findings we generated proteins comprising more than one albumin-binding DARPin ® domain. Surprisingly, we find that the use of two albuminbinding DARPin ® domains with binding specificity for serum albumin further improves the pharmacokinetic profile (Fig. 4 , Table II and twice domains #6. Terminal half-lives were determined, using the values in the range of 0.33 days to 7 days, to be T 1/2 = 4.7 days and T 1/2 = 7.7 days, respectively. Error bars indicate the standard deviation observed for the individual measurement points. The schematic molecule representations used in this figure are analogous to the ones in Fig. 1 (Deo et al., 1974; Chaudhury et al., 2003) . Interestingly, the terminal half-life values observed for the constructs comprising two serum albumin-binding DARPin ® domains appear to be beyond the reported half-life values of mouse and cynomolgus monkey serum albumin. The increase of terminal half-life in mouse and cynomolgus monkey upon fusion of multiple serum albumin-binding DARPin ® domains was confirmed by the analysis of additional proteins comprising multiple domains (Fig. 4) . A construct comprising two serum albumin-binding DARPin ® domains and one non-serum albumin-binding domain exhibits improved pharmacokinetics in mouse compared to a construct comprising only one serum albumin-binding DARPin ® domain (Fig. 4a) . Similarly, a construct comprising two serum albumin-binding DARPin ® domains and two non-serum albumin-binding domains exhibits an improved terminal half-life in cynomolgus monkey compared to a construct comprising only one serum albumin-binding DARPin ® domain (see Fig. 4b ; T 1/2 = 7.7 days and T 1/2 = 4.7 days, respectively). As domain #6 has no explicit binding specificity, specific target-mediated effects can be ruled out to cause the effect. Size-exclusion chromatography analyses coupled to multi-angle light scattering show that two serum albumin molecules can be bound at the same time in constructs comprising two serum albumin-binding DARPin ® domains (Fig. 5) , which was further confirmed by surface plasmon resonance (SPR) (data not shown). Interestingly, no effects on pharmacokinetic properties of corresponding constructs in mice were reported in previous studies using two albumin-binding domains of streptococcal protein G (Hopp et al., 2010) . Additional preclinical data on MP0250, a four-domain DARPin ® drug candidate comprising two DARPin ® domains with binding specificity for serum albumin are described elsewhere and confirm that the use of two serum albumin-binding DARPin ® domains is a useful approach to maximize terminal half-life of therapeutic proteins (Binz et al., 2017) . Further studies will be needed to elucidate the cause for the unexpected gain in terminal half-life length by adding a second albumin-binding DARPin ® domain. The Stokes radius of the construct is increasing when binding two serum albumin-binding molecules (Fig. 5) , which could reduce the amount of protein that leaves the blood by kidney filtration. This could lead to an increased apparent half-life of the bound serum albumin molecules beyond the one known for free serum albumin. Alternatively, valency could play an important role during endosomal recycling protecting the protein in case serum albumin is being degraded, by offering an escape via interaction to an intact second serum albumin molecule. This would also explain the possibility of reaching half-lives beyond the half-life of serum albumin. Further studies will be needed to describe the cause of the effect observed in more detail, in particular considering the data of Hopp et al. (2010) that suggest no effect of increased affinity, increased valency, or increased stokes radius.
Extrapolation to human -favorable pharmacokinetic profile expected
In mouse and cynomolgus monkey pharmacokinetic studies, half-lives matching the one of the respective species serum albumin are achieved using the serum albumin-binding DARPin ® domain technology (Table II) . By scaling using the data shown here, a terminal half-life in human would be predicted in the range varying from 4.7 days to 50.3 days considering mouse (18 g), cynomolgus monkey (5 kg), and human (80 kg) (Table II) . Similar to the situation in mice and cynomolgus monkey, it can be assumed that the terminal half-life of a monovalent serum albumin-binding DARPin ® domain is limited to that of serum albumin in humans, i.e. approximately 19 days (Peters, 1985) . A favorable terminal half-life in human is thus to be expected, enabling low-frequency dosing of drug candidates, comparable to human IgG antibodies. This favorable pharmacokinetic feature potentially enables dosing regimens comparable to the ones of monoclonal antibodies. Indeed, the analysis of the pharmacokinetic properties of MP0250 in cynomolgus monkey recently confirmed that drug candidates with favorable pharmacokinetic profiles can be achieved (Binz et al., 2017) .
Conclusion
Serum 
Materials and Methods
Ribosome display selections, protein engineering, and initial characterization
The selection of serum albumin-binding DARPin ® domains was performed by ribosome display (Hanes et al., 1998) using biotinylated HSA, libraries of designed ankyrin repeat proteins and protocols as described (Binz et al., 2003 (Binz et al., , 2004 Zahnd et al., 2007) . Five selection rounds on biotinylated HSA (EZ-Link™ Sulfo-NHS-Biotin, ThermoFisher; HSA from CSL Bering or Sigma), immobilized via neutravidin, were performed during which the number of reverse transcription PCR cycles constantly reduced from 40 to 30, adjusting to the yield due to enrichment of binders. DNA pools were ligated into expression vector pQE30 (Qiagen) and E. coli XL1-Blue (Stratagene) were transformed with the ligation mixes. Individual colonies were grown overnight at 37°C in 96-deep-well plates containing 1 ml/well growth medium (2YT containing 1% glucose and 100 μg/ml ampicillin). One ml/well of fresh 2YT containing 50 μg/ml ampicillin was inoculated with 100 μl of the overnight culture in fresh 96-deep-well plates. After incubation for 2 h at 37°C, expression was induced with IPTG (1 mM final concentration) and continued for 3 h. Cells were harvested, resuspended in 100 μl B-PERII (Pierce) and incubated for 15 min at room temperature with shaking. About 900 μl PBS-TC (PBS supplemented with 0.25% Casein hyrolysate, 0.1% Tween 20, pH 7.4) were added and cell debris were removed by centrifugation. About 100 μl/well of each lysate were applied to NeutrAvidin coated MaxiSorp plates containing either HSA, MSA, or CSA or the unrelated maltose-binding protein immobilized via their biotin moiety and incubated for 1 h at room temperature. After extensive washing with PBS-T (PBS supplemented with 0.1% Tween 20, pH 7.4) ELISAs were developed using the monoclonal anti-RGS(His) 4 antibody (34 650, Qiagen) as primary antibody and a polyclonal goat anti-mouse antibody conjugated with alkaline phosphatase (A3562, Sigma) as secondary reagent. Binding was then detected by using disodium 4-nitrophenyl phosphate (4NPP, Fluka) as a substrate for alkaline phosphatase. The color development was measured at 405 nm. The DNA sequences of colonies resulting in an ELISA signal were determined using standard methods. This study focusses on one sequence family. In this family, the C-terminal capping repeat steming from the DARPin ® libraries (Binz et al., 2003) has been exchanged as described (Interlandi et al., 2008; Steiner et al., 2012) , and the four variants shown here comprise different combinations of framework mutations that have been observed in that sequence family. The proteins were modified using site-directed mutagenesis or DNA synthesis.
Cloning of proteins consisting of multiple DARPin
® domains
Proteins comprising more than one DARPin ® domain were either generated by conventional PCR-cloning methods or by standard gene synthesis. The non-serum albumin-binding domains #5 and #7 have picomolar affinity to VEGF (mouse, cynomolgus monkey, and human; data not shown), whereas domain #6 is a full consensus designed ankyrin repeat domain with no known binding specificity .
Protein expression, purification and stability measurements
Selected clones were expressed in E. coli BL21 or XL1-Blue cells as described (Binz et al., 2003) and purified either using immobilized metal ion affinity chromatography as described (Binz et al., 2003) or using standard anion exchange chromatography (Q-Sepharose FF, GE Healthcare) followed by size-exclusion chromatography (Superdex 200, GE Healthcare). Protein purity >95% was verified using SDS-15% PAGE. For stability studies, proteins were concentrated to approximately 30 mg/ml (approximately 2 mM) in PBS and stored for 28 days at 40°C (stability study). Samples were taken at study start and Day 28. Samples were diluted to 500 μM and analyzed by size-exclusion chromatography using a HPLC system (Agilent 1200 series) using a Superdex 200 5/150 column (GE Healthcare) at 20°C and 0.2 ml/min flow in PBS. Aprotinin (M W 6.5 kDa), Carbonic Anhydrase (M W 29 kDa) and Conalbumin (M W 75 kDa) were used as standards for apparent molecular weight determination of the sample proteins. Thermal stability of proteins was analyzed in a fluorescence-based thermal stability assay (Niesen et al., 2007) by mixing 80 μM protein (either in PBS pH 7.4 or MES buffer pH 5.8) with 1x SYPRO orange (Invitrogen) in 50 μl volume and using a C1000 thermal cycler with a CFX96 optical system (BioRad; ramp 20°C to 95°C at 0.5°C increments including a 25 s hold step after each temperature increment; excitation 515-535 nm, detection 560-580 nm; buffer signal subtraction).
Surface Plasmon Resonance
SPR was measured using a ProteOn instrument (BioRad). Running buffer was PBS, pH 7.4, containing 0.01% Tween 20. Approximately 2000 resonance units (RU) anti-RGS-His antibody (Qiagen, cat. no. 34 650) were immobilized covalently on a GLC chip (BioRad). 150 μl of 1 μM protein solution were then injected in 300 s (flow rate = 30 μl/min) for protein immobilization via the antibody. Serum albumin of different species (400, 200, 100, and 50 nM each; human, cynomolgus monkey, mouse, rat, rabbit or dog serum albumin) in PBS containing 0.01% Tween were injected for 1 min at 100 μl/min, followed by a running buffer flow for 10 to 30 min. The signals of an uncoated reference cell and a reference injection were subtracted from the signals (double-referencing). Kinetic interaction parameters were determined using the ProteOn software (BioRad). The experiments at pH 6.0 were performed as described above, using a phosphate/citrate buffer (PBS pH-adjusted using 1 M citric acid).
Multi-angle static light scattering coupled to size-exclusion chromatography (SEC-MALS) MP0250 (30 μM; for amino acid sequence see Bakker et al., (2016) ), purified HSA (60 μM), as well as MP0250/HSA mixture (30 μM/ 60 μM) were analyzed. SEC-MALS was performed on a Agilent 1200 system (Life Technologies, USA) connected to a Wyatt (USA) MALS and refractive index detector (flow rate: 0.6 ml/min; injection volume: 100 μl; column: GE Healthcare (USA) Superdex200 10/ 300GL). The MP0250/HSA mixture was pre-incubated for 3 h at 20°C prior injection. The chromatograms are shown in Fig. 5 and the molecular masses of the eluates were determined and compared to the theoretical molecular masses (see figure legend of Fig. 5 ). For this experiment, 100 mg HSA (CSL Behring 20% solution) were purified using a Superdex 200_26.60 column on a AEKTA prime system (GE Healthcare; 2.0 ml/min, PBS, isocratic flow, injection volume 10 ml of 1:20 in PBS diluted HSA, collecting 4 ml fractions). The peak fraction of the main peak was used for performance of the SEC-MALS experiment.
Mouse pharmacokinetic studies
The studies were performed as described previously (Waibel et al., 1999) . In brief, proteins (40 μg) were incubated with 99m Tc-carbonyl (0.8-1.6 m Ci) for 1 h before dilution to 400 μl in PBS (pH 7.4). The pharmacokinetic profile was measured in one mouse per construct for ethical reasons. Each mouse was injected intravenously with 100 μl of the labeled protein solution (equivalent to 10 μg protein and 0.2-0.4 m Ci; tail vein). Blood samples of the mice were collected at 1 h, 4 h, 24 h and 48 h after the initial injection, the radioactivity of the samples was measured and the percentage injected dose (%ID) was ploted over time. The pharmacokinetic parameters including terminal half-life values were derived.
Cynomolgus monkey pharmacokinetic studies
Proteins diluted in PBS were injected as a bolus injection in the cephalic vein of cynomolgus monkeys at doses of 0.5 mg/kg to 1 mg/kg. The pharmacokinetic profile was measured in one cynomolgus monkey per construct for ethical reasons. Blood was collected from the femoral vein at various time points followed by plasma generation. Protein concentration was determined using a sandwich ELISA. Plasma samples as well as standards were serially diluted in PBS-C (PBS containing 0.25% casein, pH 7.4) and added to MaxiSorp plates that were coated with an anti-DARPin ® domain specific rabbit monoclonal antibody (generated using conventional immunization and hybridoma technologies). Binding protein was detected using an anti-RGS(His)4 antibody HRP conjugate (Qiagen) and a standard ELISA development using 100 μl BM-Blue POD substrate (Roche Diagnostics), stopped by adding 50 μl of 1 M H 2 SO 4 , followed by measurement of the absorbance at 450 nm (and subtracting the absorbance at 620 nm). The concentration of the protein in the plasma sample was calculated by performing a monoexponential regression on a standard curve of the protein diluted in monkey serum using the software Prism (GraphPad Software). Pharmacokinetic parameters were determined by non-compartmental analyses using the software Phoenix WinNonLin (Certara) or by non-linear regressions (two-phase decay; Prism), using concentration values up to 240 h after injection. In case of two-phase decay, the half-life value of the second (beta) phase was taken as terminal plasma half-life.
Alometric scaling
Allometric scaling (Ings, 1990; Ling et al., 2009) to human (80 kg) listed in Table II was calculated asuming mouse (18 g) and cynomolgus monkey (5 kg) weights and using the values for half-life listed in Table II , ploting log(half-life) as a function of log(weight) and extrapolating to the human body weight.
Supplementary data
Supplementary data are available at Protein Engineering, Design & Selection online.
